Daily semaglutide: what the evidence says about how Wegovy is dosed

What the trial evidence established about weekly dosing

The weekly injection interval for Wegovy is not arbitrary. Semaglutide has a plasma half-life of roughly one week, which is why researchers designed the STEP programme around a once-weekly injection rather than a daily one. In the STEP 1 trial published in the New England Journal of Medicine, 68 weeks of once-weekly semaglutide 2.4mg produced an average body-weight reduction of around 15%, a figure that would not have been achievable with erratic or more frequent dosing. The pharmacokinetics do the work: the molecule accumulates slowly in the body, reaching steady state over several weeks. Missing a day here and there is not really possible when your next dose is a full week away. That stability is part of the design.

This is worth knowing because some readers searching for "daily semaglutide" have come across compounded or unlicensed preparations sold online on more frequent schedules, and if you want a clear answer on whether Wegovy is taken daily or weekly, the licensed prescribing information leaves no room for ambiguity. The MHRA has warned clearly about the risks of obtaining GLP-1 medicines from sellers operating outside the licensed supply chain. Any Wegovy product dispensed by a legitimate UK pharmacy follows the weekly schedule set out in the licensed prescribing information, no legitimate prescriber will recommend otherwise.

Rybelsus versus Wegovy: the daily semaglutide confusion explained

Rybelsus is the product most people encounter when they search for daily semaglutide. It is a tablet containing the same active molecule, taken once every morning on an empty stomach, and it is licensed in the UK for type 2 diabetes at doses of 3mg, 7mg, and 14mg. It is not licensed for weight management. If a prescriber or website suggests Rybelsus as a route to weight loss, that is an off-label use, and in the UK context it raises immediate clinical and regulatory questions worth taking seriously.

The regulatory status of semaglutide as a prescription-only medicine applies equally to Rybelsus and Wegovy. Neither can be legally supplied without a valid prescription following a proper clinical assessment. The products exist in different lanes for sound clinical reasons, and a prescriber who knows your medical history is the right person to decide which, if any, is appropriate for you.

For a fuller picture of how the injection and the newer oral weight-loss tablet compare, the semaglutide overview on this site covers both licensed options in detail.

The Wegovy tablet: a new kind of daily semaglutide for weight loss

There is now one licensed daily semaglutide product for weight loss in the UK, though it is very new. On 11 June 2026 the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer called SNAC) making the UK the first country in Europe to license an oral GLP-1 medicine specifically for weight management.

The dose schedule (1.5mg, 4mg, 9mg, then 25mg maintenance, with at least a month at each level) is completely separate from the Rybelsus diabetes ladder. The tablet is taken first thing each morning with a small amount of plain water, before any food, coffee or other medicines, and you wait at least 30 minutes before eating. Unlike the injection, it needs no refrigeration, which some people find suits their routine, though it does require that consistent morning window to work as intended. In the OASIS 4 phase 3 trial, participants who adhered fully to the tablet lost around 17% of body weight over 64 weeks, with an average across all participants of roughly 13.6%.

If you're weighing up which format might suit you, cost is one factor, and the Wegovy cost and access guide sets out what private treatment typically involves in 2025 and 2026. Wegovy tablets are not currently available on the NHS; a NICE appraisal would be required before that changes.

Eligibility, clinical assessment and what happens next

Both Wegovy formats are prescription-only medicines. The injection is licensed for adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. The 7.2mg single-dose pen approved by the MHRA in April 2026 carries a BMI threshold of 30 or above. The tablet carries similar criteria. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

A prescriber considers your full picture (medical history, current medicines, weight-related conditions) before deciding which treatment, and which starting dose, is clinically appropriate. The dose increases that follow are also clinical decisions, not something to self-manage. Our clinical team reviews every consultation personally; the process is described in full on the treatment page. Timing your order is straightforward: place it by midday Monday to Friday and, once your prescriber has reviewed and approved it, your treatment is dispatched the same day.

If you have broader questions about which weight-loss treatment might suit your circumstances, the weight-loss options overview covers the licensed medicines available through nume (including how semaglutide compares to tirzepatide) and the FAQs address common practical questions about the consultation and delivery process. You can also read more about the injection format specifically at the Wegovy guide, or visit the Daily Chemist Wegovy page if you came here from that route and want details specific to ordering through this pharmacy.